<code id='C1C0FFEB26'></code><style id='C1C0FFEB26'></style>
      • <acronym id='C1C0FFEB26'></acronym>
      <center id='C1C0FFEB26'><center id='C1C0FFEB26'><tfoot id='C1C0FFEB26'></tfoot></center><abbr id='C1C0FFEB26'><dir id='C1C0FFEB26'><tfoot id='C1C0FFEB26'></tfoot><noframes id='C1C0FFEB26'>
      • <optgroup id='C1C0FFEB26'><strike id='C1C0FFEB26'><sup id='C1C0FFEB26'></sup></strike><code id='C1C0FFEB26'></code></optgroup>
        5. <b id='C1C0FFEB26'><label id='C1C0FFEB26'><select id='C1C0FFEB26'><dt id='C1C0FFEB26'><span id='C1C0FFEB26'></span></dt></select></label></b><u id='C1C0FFEB26'></u>
          <i id='C1C0FFEB26'><strike id='C1C0FFEB26'><tt id='C1C0FFEB26'><pre id='C1C0FFEB26'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / comprehensive      
           
     
           
      
          comprehensive 
           
      
           
      
           
       2025-10-06 07:49:40 
   
      
           
      
           
                        
          comprehensive  
          
                                   
                 
                                      author：fashion   
                                        
                                      
                                      Page View：1319
                                  
                                    
          
                                   
          Alastair Grant/AP
          LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.
          The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.
          advertisement
          AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe													Log In											
                      
                              
          
                                 Previous article：

                                
                                          STAT Summit: Ending the crisis of Black deaths in the U.S.
                                
                            
          Next article：  
                                      
                                          Virginia high school admissions case could be legal follow
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles